+高级检索
细胞选择性穿膜肽的穿膜效果研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Study on Transmembrane Delivery of Tumour Lineage-homing Cell-penetrating Peptides
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    细胞穿膜肽是一类能够穿透细胞膜并且不损坏细胞膜结构的小分子多肽,该多肽一般由不多于30个氨基酸组成. 针对FITC标记的具有肺癌或肝癌细胞选择性的两种穿膜肽,设置不同浓度梯度,分别处理多种肿瘤细胞,荧光显微镜下观察不同作用浓度下细胞中绿色荧光的强弱,并通过流式细胞仪检测含有荧光的细胞数. 结果表明:两种细胞穿膜肽具有不同的细胞选择性. CPP33在作用浓度为10 μmol/L时能观察到较强的荧光选择性,流式细胞仪检测含有荧光的细胞数约大于50%,CPP44在作用浓度为10 μmol/L时能观察到较强的荧光选择性,流式细胞仪检测含有荧光的细胞数约大于60%. 并且随着作用浓度的增加,两种细胞中含有荧光的细胞数不断上升. 因此这种针对肿瘤细胞的选择性穿膜肽可能为小分子药物在体内的精确递送提供一种新的方法.

    Abstract:

    Cell penetrating peptides are small molecular peptides that can penetrate cell membranes without damaging the structure of cell membranes. These peptides are generally composed of no more than 30 amino acids. Two tumor lineage-homing cell-penetrating peptides labeled with FITC for lung cancer and liver cancer were synthesized and added to different kinds of tumor cells with different concentration gradients. The number of cells containing fluorescence was detected. The results approved that the two kinds of cell-penetrating peptides showed different cell selectivity. The fluorescence specificity of CPP33 was strong at the concentration of 10 μmol/L. The number of cells containing fluorescence was about 50% by Flow cytometer. The fluorescence specificity of CPP44 was strong at the concentration of 10 μmol/L. The number of cells containing fluorescence was about 60% by Flow cytometer. Moreover, the number of cells containing fluorescence increased with the increase of concentration, respectively. In conclusion, these tumor lineage-homing cell-penetrating peptides may provide a new method for precise delivery of anticancer molecules in vivo.

    参考文献
    相似文献
    引证文献
文章指标
  • PDF下载次数:
  • HTML阅读次数:
  • 摘要点击次数:
  • 引用次数:
引用本文

谭拥军?覮,王坤,余雳,黄小芹,陈燕,谭桂湘.细胞选择性穿膜肽的穿膜效果研究[J].湖南大学学报:自然科学版,2019,46(6):83~87

复制
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-06-21
  • 出版日期:
作者稿件一经被我刊录用,如无特别声明,即视作同意授予我刊论文整体的全部复制传播的权利,包括但不限于复制权、发行权、信息网络传播权、广播权、表演权、翻译权、汇编权、改编权等著作使用权转让给我刊,我刊有权根据工作需要,允许合作的数据库、新媒体平台及其他数字平台进行数字传播和国际传播等。特此声明。
关闭